Q&A with Timothy Oostdyk, Executive Vice-President and Chief Operating Officer of Lancaster Laboratores - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Timothy Oostdyk, Executive Vice-President and Chief Operating Officer of Lancaster Laboratores

Pharmaceutical Technology
Volume 33, Issue 9, pp. 78



PharmTech:
Do you see a new industry trend emerging?

Oostdyk:
Nearly every segment of our industry is experiencing unprecedented financial pressure. People are being required to do more with less. As the pharmaceutical industry tightens its belt, a few trends are emerging.

First, faced with headcount restrictions and reductions, more pharmaceutical and biopharmaceutical companies are looking to us to meet their business objectives while enabling them to maintain a variable cost structure. This has resulted in significant growth of full-time equivalent (FTE) programs and Professional Scientific Staffing (PSS) programs. FTE programs provide dedicated staff in one of our facilities, and PSS programs provide scientific staff in the client's facility. Both models provide cost-effective solutions to our clients' staffing challenges while minimizing their own fixed headcount.

Second, as companies seek to leverage global capabilities more effectively, they are looking for international service providers who can effectively manage the logistics and communication challenges of operating worldwide. Companies require providers that offer rapid access to real-time data and highly effective project management.

Third, we see significant diversification in the pipeline of much of the industry, as companies merge and acquire products. Companies are therefore looking for laboratory service providers with extensive expertise in synthetic pharmaceuticals and biologics, as well as all types of dosage forms.

PharmTech:
What is the most common demand your clients are currently making of you?

Oostdyk:
Today more than ever, our customers are looking for a highly skilled partner that can fulfill all of their needs, from a relatively simple test to the design and execution of a complex testing program to bring a new biologic to market. We have invested in a comprehensive range of scientific services, expertise, and capacity for both traditional pharmaceutical products and biologics. This extensive range of capabilities in our laboratories, combined with our on-site staffing model, enables us to deliver a strategic solution.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here